The United States of America, as Represented by the Secretary, Department of Health and Human Services

Kite Pharma, Inc.

Teneobio, Inc.

James Noble Kochenderfer

Steven A Rosenberg

Nathan D Trinklein

Wim Van Schooten

Shelley Force Aldred

Adrian I Bot

Rajul Jain

Jeffrey S Wiezorek

William Go

Steven A Feldman

Norris Lam

Katherine E Harris

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Methods of conditioning patients for T cell therapy

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

Chimeric antigen receptors targeting B-cell maturation antigen

Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.

Anti-SLAMF7 chimeric antigen receptors

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

Diagnostic methods for T cell therapy

The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.

Chimeric antigen receptors targeting CD-19

Chimeric antigen receptors targeting b-cell maturation antigen

Growing community of inventors

Bethesda, MD, United States of America

James Noble Kochenderfer